eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 14
State of the art paper

Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009–2014

Małgorzata Tłustochowicz, Andrzej M. Śliwczyński, Melania Brzozowska, Zbigniew Teter, Michał Marczak

Arch Med Sci 2018; 14, 3: 569–571
Online publish date: 2016/03/31
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Approximately 1% of the population suffers from rheumatoid arthritis (RA) worldwide (0.45% in Poland). The therapy consists of the use of disease-modifying antirheumatic drugs (DMARDs). Biologics are used in the form of the drug programme. Analysis of the NHF database demonstrated the sequence of conversion between drugs and time spent in a single treatment. In 2009, the patients would start the following treatments: adalimumab 5.8%; etanercept 14.4%; infliximab 23.1%; leflunomide 53.6%; rituximab 3%. After the first year 16% of patients changed therapy or abstained, and in the second year this situation affected 65% of patients. The following percentages maintained the same treatment in the last 6 years: infliximab 4%; adalimumab 15%; etanercept 21%; leflunomide on prescription was continued by 70%. Patients remain too long on the same therapy when it is inefficient. Achieving remission or low disease activity (DAS28 < 2.6) should take place within 6 months of starting therapy.

biological drug, rheumatoid arthritis, sequentiality of treatment

Silman AJ, Hochberg MC. Epidemiology of the rheumatic diseases, rheumatoid arthritis. Oxford Univerity Press, New York 2001; 31-71.
Iltchev P, Śliwczyński A, Czeleko T, et al. Rheumatoid arthritis morbidity rate in Poland in the years 2008-2012 in rural and urban areas. Ann Agricult Envirom Med Lublin 2016; 23, 2 (in print).
Filipowicz-Sosnowska A, Stanisławska-Biernat E, Zubrzycka-Sienkiewicz A. Rheumatoid arthritis [Polish]. Reumatologia 2004; 42 (Suppl.): 8-13.
Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580-8.
Lis K, Kuzawińska O, Bałkowiec-Iskra E. Tumor necrosis factor inhibitors – state of knowledge. Arch Med Sci 2014; 10: 1175-85.
National Institute for Clinical Excellence. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis, Technology Appraisal No 36, March 2002.
Description of drug programs – appendix B33 in http://www.mz.gov.pl/leki/refundacja/lista-lekow-refundowanych-obwieszczenia-ministra-zdrowia, accessed on 26.10.2015.
Smolen J, Landewé R, Breedveld F, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509.
Klareskog L, van der Heijde D, de Jager JP, et al.; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
St Clair EW, van de Heijde D, Smolen JS, et al.: Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum 2004; 50: 3432-43.
Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum 2006; 54: 1390-14.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe